Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, wa...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2020-12-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12885-020-07701-8 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|